secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENANTA PHARMACEUTICALS INC (ENTA)
CIK:        0001177648
Form:       8-K
Filed at:   2026-07-02T20:56:37+00:00
Accession:  0001193125-26-294837
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enanta enters ATM equity agreement with Jefferies for up to $75M
----------------------------------------------------------------

- Open Market Sale Agreement with Jefferies LLC as sales agent for at-the-market offerings.
- Enanta may sell up to $75M of common stock from time to time on Nasdaq.
- Jefferies will receive a commission of up to 3.0% of gross sales price per share.
- Enanta has no obligation to sell any shares under the agreement.
- Prospectus supplement filed July 2, 2026; shelf registration effective February 20, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1177648/000119312526294837/0001193125-26-294837-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1177648/000119312526294837/d123412d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-294837

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer